Jet nebulisers for pulmonary drug delivery

McCallion, Orla; Taylor, Kevin; Bridges, Paul A.; Thomas, M.; Taylor, A J Newman

doi:10.1016/0378-5173(95)04233-4

Cited by 73 publications

(40 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The duration of nebulization and treatment should also be considered, given their impact on patient compliance. 21,22 Indeed, shorter treatment durations are associated with increased patient compliance. Although this criterion is not very relevant for mechanical ventilation, it may be important in ambulatory care.…”

Section: Duration Aerosol Output Albuterol Deposition and Temperaturementioning

confidence: 99%

“…With the jet nebulizer, the drop in temperature can be explained by an evaporation of the solution created by the anhydrous propellant gas flow, as already observed in other studies. 13,22 In the clinic, the administration of cold air and hypo-or hypertonic solutions can induce paradoxical bronchospasms. 27 With the ultrasonic nebulizer (ultrasonic frequency 1.7 MHz), a sudden temperature increase characterizes the end of nebulization, as most of the energy absorbed by the nebulizer solution is dissipated as heat.…”

Section: Duration Aerosol Output Albuterol Deposition and Temperaturementioning

confidence: 99%

See 1 more Smart Citation

Physicochemical Aspects and Efficiency of Albuterol Nebulization: Comparison of Three Aerosol Types in an In Vitro Pediatric Model

Sidler-Moix

Paolo²,

Dolci³

et al. 2014

Respir Care

View full text Add to dashboard Cite

BACKGROUND: Advances in nebulizer design have produced both ultrasonic nebulizers and devices based on a vibrating mesh (vibrating mesh nebulizers), which are expected to enhance the efficiency of aerosol drug therapy. The aim of this study was to compare 4 different nebulizers, of 3 different types, in an in vitro model using albuterol delivery and physical characteristics as benchmarks. METHODS: The following nebulizers were tested: Sidestream Disposable jet nebulizer, Multisonic Infra Control ultrasonic nebulizer, and the Aerogen Pro and Aerogen Solo vibrating mesh nebulizers. Aerosol duration, temperature, and drug solution osmolality were measured during nebulization. Albuterol delivery was measured by a high-performance liquid chromatography system with fluorometric detection. The droplet size distribution was analyzed with a laser granulometer. RESULTS: The ultrasonic nebulizer was the fastest device based on the duration of nebulization; the jet nebulizer was the slowest. Solution temperature decreased during nebulization when the jet nebulizer and vibrating mesh nebulizers were used, but it increased with the ultrasonic nebulizer. Osmolality was stable during nebulization with the vibrating mesh nebulizers, but increased with the jet nebulizer and ultrasonic nebulizer, indicating solvent evaporation. Albuterol delivery was 1.6 and 2.3 times higher with the ultrasonic nebulizer and vibrating mesh nebulizers devices, respectively, than with the jet nebulizer. Particle size was significantly higher with the ultrasonic nebulizer. CONCLUSIONS: The in vitro model was effective for comparing nebulizer types, demonstrating important differences between nebulizer types. The new devices, both the ultrasonic nebulizers and vibrating mesh nebulizers, delivered more aerosolized drug than traditional jet nebulizers.

show abstract

Section: Duration Aerosol Output Albuterol Deposition and Temperaturementioning

confidence: 99%

Section: Duration Aerosol Output Albuterol Deposition and Temperaturementioning

confidence: 99%

Physicochemical Aspects and Efficiency of Albuterol Nebulization: Comparison of Three Aerosol Types in an In Vitro Pediatric Model

Sidler-Moix

Paolo²,

Dolci³

et al. 2014

Respir Care

View full text Add to dashboard Cite

show abstract

“…Deposition of aerosols in mice depends on aerosol particle size, which is affected by delivery device, formulation parameters, 13,14 and the breathing pattern. For tidal breathing, the optimal particle size for alveolar deposition is 3 mm in both humans and mice, but for tracheobronchial deposition it is approximately 6 mm in humans and 4 mm in mice.…”

Section: 11mentioning

confidence: 99%

Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs

Nadithe

Rahamatalla

Finlay

et al. 2003

Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

“…8 Addition of micronized lactose to coarse lactose carrier was found to improve the dispersion and deaggregation of salbutamol sulfate and spray-dried bovine serum albumin. [9][10] Also, techniques such as spray drying the drug with phospholipid composites in a suitable range for pulmonary delivery 11 or the dissolution of lecithin in chlorofluorohydrocarbon and the formation of liposomes in situ 12 or nebulization of the preformed liposomes 13 can be attempted for liposomal drug delivery to lungs. Recently, many microparticle systems have been reported to be used for pulmonary drug delivery such as oligosaccharide ester derivative (OED), [14][15] biodegradable ether-anhydride polymer, 16 sodium hyaluronate, 17 and poly(lactic-co-glycolic acid) (PLGA).…”

Section: Introductionmentioning

confidence: 99%

Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance

Shah

Misra

2004

AAPS PharmSciTech

View full text Add to dashboard Cite

The aim of the present investigation was to prepare and evaluate the influence of adding fines on the in vitro performance of liposomal amikacin dry powder inhaler (AMK LDPI) formulations. Liposomes composed of hydrogenated soyaphosphatidylcholine, cholesterol and saturated soyaphosphatidylglycerol (AMK 1), or stearylamine (AMK 2) were prepared by a reverse phase evaporation technique, extruded to reduce size and separated from unentrapped drug. Purified liposomal dispersion was subjected to lyophilization using optimized cryoprotectant to achieve maximum percentage drug retention (PDR). Lactose carrier in varying mass ratios with or without addition of fines in different mixing sequences was used to formulate AMK LDPI formulations. AMK LDPI formulations were characterized for angle of repose, compressibility index, dispersibility index, scanning electron microscopy, and fine particle fraction (FPF). PDR was found to be 97.6% ± 2.2% for AMK1 and 98.5% ± 1.9% for AMK2 using sucrose as optimized cryoprotectant in lipid:sucrose ratio of 1:4. Lactose carrier containing 10% fines (wt/wt) was found to be the optimum blend at 1:5 mass ratio of liposome:lactose. The addition of fines and the order of mixing of fines were found to influence the FPF with significantly different device fractions. FPF of AMK LDPI formulations using Rotahaler as the delivery device at 30, 60, and 90 L/min were found to be 21.85% ± 2.2% and 24.6% ± 2.4%, 25.9% ± 1.8% and 29.2% ± 2.1%, and 29.5% ± 2.6% and 34.2% ± 2.0% for AMK1 and AMK2, respectively. From the studies performed in this investigation, it was observed that liposomal charge, addition of fines and order of mixing fines, has a significant effect (P < .05) on in vitro deposition of drug from LDPI formulation.KEYWORDS: liposomes, dry powder inhalers, amikacin, lactose, fines, fine particle fraction INTRODUCTIONAmikacin sulfate (AMK) is a broad-spectrum and potent aminoglycoside with limited clinical use owing to a high dose requirement and renal and audio-vestibular apparatus toxicity. 1-2 Major drawbacks associated with the use of earlier or conventional liposomal formulations are the tendency of liposomes to leak drug while in circulation, the extensive uptake of these liposomes by tissues of reticuloendothelial systems (RES), and the inability of liposomes to extravasate into infected tissue. 3-4 Therefore, localized liposomal AMK delivery was considered for the treatment of cystic fibrosis infections in the lungs. Liposomal encapsulation of AMK will give the required release of drug for a longer time duration at the localized site, thereby reducing both the chances of systemic side effects and the frequency of dosing.Improving drug delivery to the lungs from a dry powder inhaler (DPI) formulation is possible by various techniques such as smoothing the carrier surface, 5 reducing the particle size of the carrier, 6-7 and using a ternary powder mix formulation. 8 Addition of micronized lactose to coarse lactose carrier was found to improve the dispersion and deaggregation o...

show abstract

Jet nebulisers for pulmonary drug delivery

Cited by 73 publications

References 48 publications

Physicochemical Aspects and Efficiency of Albuterol Nebulization: Comparison of Three Aerosol Types in an In Vitro Pediatric Model

Physicochemical Aspects and Efficiency of Albuterol Nebulization: Comparison of Three Aerosol Types in an In Vitro Pediatric Model

Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs

Liposomal amikacin dry powder inhaler: Effect of fines on in vitro performance

Contact Info

Product

Resources

About